Ke I. Kim

Kobe, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management

Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: September 03, 2019

Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.

Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.

Journal: Digestive diseases (Basel, Switzerland)

Published: October 18, 2017

Coffee Intake and Liver Enzyme Association in Korean Immigrants and Japanese: A Comprehensive Cross-Sectional Study.

Coffee Intake and Liver Enzyme Association in Korean Immigrants and Japanese: A Comprehensive Cross-Sectional Study.

Journal: Digestive diseases (Basel, Switzerland)

Published: October 18, 2016

Influence of hyperglycemia on liver inflammatory conditions in the early phase of non-alcoholic fatty liver disease in mice.

Influence of hyperglycemia on liver inflammatory conditions in the early phase of non-alcoholic fatty liver disease in mice.

Journal: The Journal of pharmacy and pharmacology

Published: September 09, 2016

A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: April 05, 2016

An Overview of NAFLD/NASH in Japan

An Overview of NAFLD/NASH in Japan

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: April 05, 2016

Current Status and Future Prospects of Nonalcoholic Fatty Liver Disease (NAFLD) in Japan-Feedback from Clinical and Basic Researches to Medical Therapy and Pharmacist Activities

Current Status and Future Prospects of Nonalcoholic Fatty Liver Disease (NAFLD) in Japan-Feedback from Clinical and Basic Researches to Medical Therapy and Pharmacist Activities

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: April 05, 2016

Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon.

Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon.

Journal: Oncology

Published: November 20, 2015

Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.

Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.

Journal: Oncology

Published: November 20, 2015

Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population.

Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population.

Journal: Digestive diseases (Basel, Switzerland)

Published: October 22, 2015

Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.

Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.

Journal: Digestive diseases (Basel, Switzerland)

Published: November 28, 2013

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.

Journal: Digestive diseases (Basel, Switzerland)

Published: November 28, 2013

Showing 1-12 of 16

Last Updated: 09/26/2026